Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients

Lignende værker

• Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
  af: Qiu, Xiaotong, et al.
  Udgivet: (2021)
• Current evidence on the cytotoxic T-lymphocyte antigen 4 + 49G > A polymorphism and digestive system cancer risks: a meta-analysis involving 11,923 subjects
  af: Xiaolei, Liu, et al.
  Udgivet: (2015)
• Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
  af: Makhlin, Igor, et al.
  Udgivet: (2019)
• Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
  af: Tabara, Keisuke, et al.
  Udgivet: (2012)
• Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
  af: Choi, Yun Jung, et al.
  Udgivet: (2013)